What specifically changed in the March 16, 2026 note on SVRA analyst rating?

H.C. Wainwright **maintained** a **Buy** rating on March 16, 2026, citing Savara’s positioning ahead of the August PDUFA. There was no new price target and the note emphasized regulatory timing rather than fresh financial estimates.

How should investors interpret a maintained Buy versus an upgrade?

A maintained Buy keeps positive analyst sentiment but signals no new conviction increase. For SVRA, the maintained stance keeps upside expectations but leaves binary regulatory risk intact until the August PDUFA.

Did the March 16 note include a new SVRA price target?

No. The H.C. Wainwright note on March 16, 2026 reiterated the Buy rating but did not publish a new SVRA price target, so valuation assumptions were not updated in that release.

Where can I read the full analyst note and related sector context?

Read H.C. Wainwright’s note via StreetInsider for the full SVRA analyst rating details [source](https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Savara+%28SVRA%29%3A+%27well+positioned+ahead+of+the+August+PDUFA+date%27). For broader biotech sector context see a

Analyst Ratings

H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026

ByHuzaifa Zahoor March 17, 2026March 17, 2026

H.C. Wainwright on March 16, 2026 maintained a Buy rating on Savara Inc. (SVRA), citing the company as “well positioned ahead of the August PDUFA date.” The SVRA analyst rating was reiterated in StreetInsider coverage that morning, leaving the firm’s stance unchanged. This confirmation matters because it keeps institutional sentiment positive ahead of a key regulatory milestone. The note coincided with a modest market move of 0.48% ($0.03), reflecting muted intraday reaction.